<DOC>
	<DOCNO>NCT00184795</DOCNO>
	<brief_summary>This trial conduct Europe . Postmenopausal woman moderate severe hot flash recruit trial . The early effect ultra low dose HRT ( hormone replacement therapy ) frequency severity menopausal symptom , bleed pattern safety different hormonal combination evaluate compare placebo six month treatment period .</brief_summary>
	<brief_title>Bleed Free Treatment Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations</brief_title>
	<detailed_description />
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Postmenopausal status Subject minimum 7 moderate severe hot flush per day , minimum 50 moderate severe hot flush per week , last 2 week runin ( screen ) period . Subject intact uterus In accordance exist label estrogen/progestogen combination Body Mass Index ( BMI ) &gt; 35.0 kg/m2 Known alcohol drug abuse , heavy smoking ( 20 cigarette day ) Currently use steroid hormone ( except topical inhalation glucocorticoid preparation ) drug know influence estrogen metabolism barbiturate , phenytoin , rifampicin , carbamazepin</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hot flash</keyword>
</DOC>